ImmunoPrecise Antibodies Ltd. (IPA) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
ImmunoPrecise Antibodies Ltd. (IPA) Bundle
Gain insight into your ImmunoPrecise Antibodies Ltd. (IPA) valuation analysis using our sophisticated DCF Calculator! This Excel template comes preloaded with real (IPA) data, enabling you to adjust forecasts and assumptions for an accurate calculation of ImmunoPrecise Antibodies Ltd.'s intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.8 | 12.4 | 13.4 | 14.3 | 17.0 | 19.6 | 22.6 | 26.0 | 30.0 | 34.6 |
| Revenue Growth, % | 0 | 27.42 | 8.11 | 6.72 | 18.65 | 15.22 | 15.22 | 15.22 | 15.22 | 15.22 |
| EBITDA | -.3 | -1.0 | -8.3 | -14.6 | -15.9 | -10.5 | -12.0 | -13.9 | -16.0 | -18.4 |
| EBITDA, % | -3.19 | -7.92 | -61.94 | -101.8 | -93.6 | -53.33 | -53.33 | -53.33 | -53.33 | -53.33 |
| Depreciation | 2.4 | 2.6 | 2.6 | 4.6 | 4.0 | 4.7 | 5.4 | 6.3 | 7.2 | 8.3 |
| Depreciation, % | 24.24 | 20.73 | 19.46 | 32.35 | 23.39 | 24.03 | 24.03 | 24.03 | 24.03 | 24.03 |
| EBIT | -2.7 | -3.6 | -10.9 | -19.2 | -19.9 | -13.2 | -15.2 | -17.6 | -20.2 | -23.3 |
| EBIT, % | -27.43 | -28.65 | -81.4 | -134.15 | -116.99 | -67.5 | -67.5 | -67.5 | -67.5 | -67.5 |
| Total Cash | 1.8 | 29.0 | 20.8 | 5.7 | 2.4 | 10.7 | 12.3 | 14.2 | 16.4 | 18.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.5 | 2.5 | 2.4 | 2.7 | 2.8 | 3.9 | 4.5 | 5.2 | 6.0 | 6.9 |
| Account Receivables, % | 26.04 | 20.25 | 17.6 | 18.77 | 16.59 | 19.85 | 19.85 | 19.85 | 19.85 | 19.85 |
| Inventories | .6 | .8 | 1.1 | 1.4 | 1.5 | 1.6 | 1.8 | 2.1 | 2.4 | 2.7 |
| Inventories, % | 5.82 | 6.72 | 8.34 | 9.97 | 8.72 | 7.92 | 7.92 | 7.92 | 7.92 | 7.92 |
| Accounts Payable | .9 | .9 | 2.7 | 1.7 | 2.8 | 2.6 | 3.0 | 3.4 | 4.0 | 4.6 |
| Accounts Payable, % | 9.63 | 7.51 | 20.23 | 12.02 | 16.61 | 13.2 | 13.2 | 13.2 | 13.2 | 13.2 |
| Capital Expenditure | -.4 | -1.0 | -.9 | -1.0 | -1.0 | -1.2 | -1.4 | -1.6 | -1.9 | -2.2 |
| Capital Expenditure, % | -4.09 | -7.97 | -6.49 | -7.23 | -5.7 | -6.3 | -6.3 | -6.3 | -6.3 | -6.3 |
| Tax Rate, % | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 |
| EBITAT | -2.5 | -4.4 | -11.5 | -18.4 | -18.9 | -12.8 | -14.8 | -17.0 | -19.6 | -22.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2.7 | -3.0 | -8.1 | -16.4 | -14.9 | -10.7 | -11.2 | -12.9 | -14.8 | -17.1 |
| WACC, % | 4.99 | 5.13 | 5.13 | 5.04 | 5.01 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -57.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -17 | |||||||||
| Terminal Value | -571 | |||||||||
| Present Terminal Value | -446 | |||||||||
| Enterprise Value | -503 | |||||||||
| Net Debt | 7 | |||||||||
| Equity Value | -510 | |||||||||
| Diluted Shares Outstanding, MM | 26 | |||||||||
| Equity Value Per Share | -19.89 |
What You Will Get
- Real IPA Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for ImmunoPrecise Antibodies Ltd. (IPA).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates tailored for IPA.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on ImmunoPrecise Antibodies Ltd.'s (IPA) fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to IPA.
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility for ImmunoPrecise Antibodies Ltd. (IPA).
Key Features
- Comprehensive Immunology Data: Access reliable pre-loaded historical performance metrics and future forecasts for ImmunoPrecise Antibodies Ltd. (IPA).
- Adjustable Research Parameters: Modify highlighted cells for critical factors like R&D expenses, market growth rates, and product margins.
- Real-Time Analytics: Automatic recalculations for DCF, Net Present Value (NPV), and revenue projections.
- Interactive Visualization Tools: User-friendly charts and summaries to effectively present your valuation outcomes.
- Designed for All Experience Levels: An intuitive layout tailored for researchers, investors, and industry experts.
How It Works
- Step 1: Download the prebuilt Excel template featuring ImmunoPrecise Antibodies Ltd. (IPA) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly observe the recalculated results, including ImmunoPrecise Antibodies Ltd.'s (IPA) intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the generated outputs.
Why Choose ImmunoPrecise Antibodies Ltd. (IPA)?
- Precision: Utilizes cutting-edge technology for accurate antibody development.
- Customization: Tailored solutions to meet specific research and therapeutic needs.
- Efficiency: Streamlined processes reduce time to market for critical discoveries.
- Expertise: Backed by a team of industry veterans with extensive experience.
- User-Centric: Designed for accessibility, catering to both seasoned scientists and newcomers.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive valuation models for analyzing ImmunoPrecise Antibodies Ltd. (IPA).
- Corporate Development Teams: Evaluate various valuation scenarios to inform strategic decisions.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in ImmunoPrecise Antibodies Ltd. (IPA).
- Students and Educators: Utilize real-world data to enhance learning in biotech financial modeling.
- Healthcare Enthusiasts: Gain insights into how biotech firms like ImmunoPrecise Antibodies Ltd. (IPA) are valued in the market.
What the Template Contains
- Pre-Filled DCF Model: ImmunoPrecise Antibodies Ltd.'s (IPA) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate ImmunoPrecise's profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.